Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN COMBINATION PACK versus MYCELEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN COMBINATION PACK versus MYCELEX.
GYNE-LOTRIMIN COMBINATION PACK vs MYCELEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity. Betamethasone, a corticosteroid, suppresses inflammatory responses via glucocorticoid receptor activation.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby disrupting ergosterol biosynthesis and compromising fungal cell membrane integrity.
Intravaginal: One 500 mg vaginal tablet inserted at bedtime as a single dose; external: Apply clotrimazole 1% cream twice daily for 7 days.
For oropharyngeal candidiasis: Clotrimazole troche 10 mg dissolved slowly in mouth 5 times daily for 14 days. For vulvovaginal candidiasis: Clotrimazole vaginal tablet 500 mg single dose or 200 mg daily for 3 days or 100 mg daily for 7 days; 1% vaginal cream 5 g intravaginally daily for 7-14 days.
None Documented
None Documented
Clotrimazole: 3.5–6 hours (terminal). Betamethasone: 5.6 hours (terminal). Clinical context: Supports twice-daily dosing for antifungal effect; betamethasone systemic exposure minimal with vaginal use.
Terminal elimination half-life is 20-50 hours (mean ~30 hours) in adults; prolonged in neonates (~40-80 hours) and in hepatic impairment.
Clotrimazole: primarily fecal (biliary) as metabolites, <0.5% unchanged in urine. Betamethasone dipropionate: renal (primarily as inactive metabolites) and biliary/fecal.
Primarily hepatic metabolism; <1% excreted unchanged in urine; ~50% of dose excreted in feces as metabolites.
Category C
Category C
Azole Antifungal
Azole Antifungal